Y Wang,
J-Q Li,
C Shao,
C-H Shi,
F Liu,
Z-Y Yang,
J-X Qiu,
Y-M Li,
Q Fu,
W Zhang,
W Xue,
Y-H Lei,
J-Y Gao,
J-Y Wang,
X-P Gao,
J-L Yuan, T-Y Bao,
Y-T Zhang
[show abstract]
[hide abstract]
ABSTRACT: Prostate cancer cells can switch from an androgen-dependent state to an androgen-independent state after a continuous androgen ablation therapy. However, the molecular mechanisms underlying this switch are still unclear. Therefore, we explored the change in androgen receptor (AR)-related gene expression during this transition in a novel cell model.
Prostate cancer cells were continuously treated with competitive androgen receptor inhibitor hydroxyflutamide for 1.5 years, which yielded an flutamide-insensitive LNCaP subline, LNCaP-flu, as confirmed by MTT assays, flow cytometry, and electron microscopy. We analyzed the differences in gene expression in LNCaP-flu cells and LNCaP cells using gene chips and follow-up RT-PCR.
Over 2,428 genes were differentially expressed between these cell lines: 1,194 were down-regulated and 1,234 were up-regulated. Three genes in particular were considered related to the androgen-dependent transition: NCOR1, TIF2 (NCOA2), and ARA70 (NCOA4). There were no apparent changes in expression of the androgen receptor or prostate-specific antigen.
ARs and associated coregulators play a central role in the flutamide-insensitive transition of prostate cancer cells. Although AR expression does not change during this transition, the change in AR coregulators may be a critical factor in the development of antiandrogen insensitivity.
Irish Journal of Medical Science 07/2011; 180(4):865-72. · 0.58 Impact Factor
